The emerging safety profile of JAK inhibitors in rheumatic disease
Oregon Health & Science University
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
580
total citations
- FWCI
- 49.79
- Percentile
- 100%
- References
- 75
Citations per year
Authors
1Topics & keywords
Topics
Keywords
- Tofacitinib
- Medicine
- Janus kinase
- Rheumatoid arthritis
- Malignancy
- Clinical trial
- Safety profile
- Ruxolitinib
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.